Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 525 of 3499 entries
View as:

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00841204 Org: User:
Start: 02/28/09 End: 02/28/11 Due: 02/28/12

Imatinib Mesylate in Treating Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00039416 Org: User:
Start: 04/30/02 End: - Due: -

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05272384 Org: User:
Start: 11/03/22 End: 06/28/27 Due: 06/28/28

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT06422806 Org: User:
Start: 09/11/24 End: 06/30/26 Due: 06/30/27

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Phase: N/A Priority: Normal
NCT ID: NCT05470491 Org: User:
Start: 01/26/23 End: 07/30/27 Due: 07/30/28

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05286801 Org: User:
Start: 11/17/22 End: 06/30/26 Due: 06/30/27

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase: N/A Priority: Normal
NCT ID: NCT06184750 Org: User:
Start: 09/27/24 End: 09/30/28 Due: 09/30/29

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Phase: N/A Priority: Normal
NCT ID: NCT06222203 Org: User:
Start: 10/09/24 End: 12/31/35 Due: 12/31/36

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Phase: N/A Priority: Normal
NCT ID: NCT05691491 Org: User:
Start: 09/28/23 End: 03/01/27 Due: 03/01/28

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01307631 Org: User:
Start: 03/31/11 End: 09/18/15 Due: 09/18/16

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00923195 Org: User:
Start: 12/31/08 End: 08/31/11 Due: 08/31/12

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00101205 Org: User:
Start: 11/30/04 End: - Due: -

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02048813 Org: User:
Start: 03/10/14 End: 01/25/26 Due: 01/25/27

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00972478 Org: User:
Start: 11/15/10 End: 03/06/26 Due: 03/06/27

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03173950 Org: User:
Start: 07/13/17 End: 07/15/26 Due: 07/15/27

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00018941 Org: User:
Start: 04/30/91 End: 05/31/03 Due: 05/31/04

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00778817 Org: User:
Start: 12/31/08 End: 03/31/14 Due: 03/31/15

Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT01036958 Org: User:
Start: 11/25/09 End: 02/06/18 Due: 02/06/19

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00003620 Org: User:
Start: 06/30/99 End: - Due: -

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Phase: N/A Priority: Normal
NCT ID: NCT00217373 Org: User:
Start: 06/30/05 End: 03/31/15 Due: 03/31/16

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04185220 Org: User:
Start: 02/26/20 End: 05/18/22 Due: 05/18/23

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00019838 Org: User:
Start: 07/31/99 End: - Due: -

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00268385 Org: User:
Start: 12/16/05 End: 04/24/26 Due: 04/24/27

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02649439 Org: User:
Start: 12/22/15 End: 10/01/22 Due: 10/01/23

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01064622 Org: User:
Start: 09/03/09 End: 01/31/13 Due: 01/31/14